Search results for " CD"

showing 10 items of 587 documents

Room-temperature performance of 3 mm-thick cadmium-zinc-telluride pixel detectors with sub-millimetre pixelization.

2020

Cadmium–zinc–telluride (CZT) pixel detectors represent a consolidated choice for the development of room-temperature spectroscopic X-ray imagers, finding important applications in medical imaging, often as detection modules of a variety of new SPECT and CT systems. Detectors with 3–5 mm thicknesses are able to efficiently detect X-rays up to 140 keV giving reasonable room-temperature energy resolution. In this work, the room-temperature performance of 3 mm-thick CZT pixel detectors, recently developed at IMEM/CNR of Parma (Italy), is presented. Sub-millimetre detector arrays with pixel pitch less than 500 µm were fabricated. The detectors are characterized by good room-temperature performan…

Nuclear and High Energy PhysicsMaterials sciencePhysics::Instrumentation and DetectorsAstrophysics::High Energy Astrophysical Phenomena02 engineering and technology01 natural sciencesDot pitchCollimated lightlaw.inventionCharge sharingchemistry.chemical_compoundOpticslaw0103 physical sciencesInstrumentation010302 applied physicsX-ray and gamma ray detectors; CdZnTe pixel detectors; charge sharing; charge losses; charge-sharing correction; spectroscopic X-ray imagingRadiationPixelbusiness.industrySettore FIS/01 - Fisica SperimentaleDetectorCdZnTe pixel detectors charge losses charge sharing charge-sharing correction spectroscopic X-ray imaging X-ray and gamma ray detectors021001 nanoscience & nanotechnologySettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)SynchrotronCadmium zinc telluridechemistry0210 nano-technologyPixelizationbusinessJournal of synchrotron radiation
researchProduct

Search for Neutral Higgs Bosons in Events with Multiple Bottom Quarks at the Tevatron

2012

The combination of searches performed by the CDF and D0 collaborations at the Fermilab Tevatron Collider for neutral Higgs bosons produced in association with b quarks is reported. The data, corresponding to 2.6fb -1 of integrated luminosity at CDF and 5.2fb -1 at D0, have been collected in final states containing three or more b jets. Upper limits are set on the cross section multiplied by the branching ratio varying between 44 pb and 0.7 pb in the Higgs boson mass range 90 to 300 GeV, assuming production of a narrow scalar boson. Significant enhancements to the production of Higgs bosons can be found in theories beyond the standard model, for example, in supersymmetry. The results are int…

Nuclear and High Energy PhysicsParticle physicsPhysics beyond the Standard ModelSTANDARD MODELP(P)OVER-BAR COLLISIONSTevatronFOS: Physical sciencesMASSLESS PARTICLES7. Clean energy01 natural sciencesHigh Energy Physics - ExperimentStandard ModelNuclear physicsHigh Energy Physics - Experiment (hep-ex)Higgs particle: search for | Higgs particle: associated production | minimal supersymmetric standard model: parameter space | bottom: multiple production | cross section: branching ratio: upper limit | benchmark | DZERO | CDF | anti-p p: interaction | experimental results | Batavia TEVATRON Coll | anti-p p --> Higgs particle bottom anything | Higgs particle --> bottom anti-bottom | 1960 GeV-cms0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]BROKEN SYMMETRIESTEVATRONMASSES010306 general physicsDETECTORSUPERSYMMETRYBosonPhysicsHIGGS BOSON010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyDETECTOR; SUPERSYMMETRY; MASSES; MSSM; ROOT-S=1.96 TEV; BROKEN SYMMETRIES; MASSLESS PARTICLES; STANDARD MODEL; P(P)OVER-BAR COLLISIONSSupersymmetryScalar bosonROOT-S=1.96 TEVExperimental High Energy PhysicsHiggs bosonComputingMethodologies_DOCUMENTANDTEXTPROCESSINGCDFHigh Energy Physics::ExperimentMSSMMinimal Supersymmetric Standard Model
researchProduct

Rat olfactory bulb and epithelium UDP-glucuronosyltransferase 2A1 (UGT2A1) expression: in situ mRNA localization and quantitative analysis.

2001

UDP-glucuronosyltransferases (UGTs) form a multigenic family of enzymes involved in the biotransformation and elimination of numerous endo- and xenobiotic compounds. Beside the diverse UGT isoforms present in the liver as well as in other tissues, the UGT2A1 isoform, also called olfactory UGT, was initially thought to be expressed in the nasal epithelium only. In this work, we demonstrate the UGT2A1 mRNA expression in the olfactory bulb, using in situ hybridization and quantitative reverse transcription-polymerase chain reaction (RT-PCR) techniques. Within the epithelium, UGT2A1 mRNA is mainly found in the sustentacular cells and to a lesser extent in Bowman's gland cells. Moreover, in situ…

Olfactory systemMaleCentral nervous systemNerve Tissue ProteinsIn situ hybridizationBiologyCellular and Molecular NeuroscienceMiceRapid amplification of cDNA endsOlfactory MucosaGene expressionmedicineAnimalsNeurons AfferentRNA MessengerGlucuronosyltransferaseRats WistarMolecular BiologyIn Situ HybridizationAir PollutantsMice Inbred BALB CSequence Homology Amino AcidReverse Transcriptase Polymerase Chain ReactionEpithelial CellsMolecular biologyOlfactory BulbEpitheliumOlfactory bulbRatsIsoenzymesmedicine.anatomical_structureInactivation MetabolicOlfactory epitheliumBrain research. Molecular brain research
researchProduct

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme

2008

Abstract Purpose: Cancer stem cells (CSC) are thought to represent the population of tumorigenic cells responsible for tumor development. The stem cell antigen CD133 identifies such a tumorigenic population in a subset of glioblastoma patients. We conducted a prospective study to explore the prognostic potential of CSC analysis in glioblastoma patients. Experimental Design: We investigated the relationship between the in vitro growth potential of glioblastoma CSCs and patient death or disease progression in tumors of 44 consecutive glioblastoma patients treated with complete or partial tumorectomy followed by radiotherapy combined with temozolomide treatment. Moreover, we evaluated by immun…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPathologyAC133 Antigen; Adult; Aged; Antigens CD; Brain Neoplasms; Female; Glioblastoma; Glycoproteins; Humans; Ki-67 Antigen; Male; Middle Aged; Multivariate Analysis; Neoplastic Stem Cells; Peptides; Prospective Studiesmedicine.medical_treatmentPopulationAntigens CDCancer stem cellInternal medicinemedicineHumansAC133 AntigenProspective StudiesAntigensProspective cohort studyeducationAgedGlycoproteinseducation.field_of_studyTemozolomideSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryBrain NeoplasmsHazard ratioMiddle AgedGliobastoma MultiformeCDRadiation therapyKi-67 AntigenOncologyMultivariate AnalysisNeoplastic Stem CellsImmunohistochemistryFemaleStem cellbusinessGlioblastomaPeptidesmedicine.drug
researchProduct

Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy i…

2002

The purpose of this study was to evaluate feasibility and efficacy of Rituximab included into a sequential salvage protocol for CD20(+) B-NHL in relapse or induction failure. Twenty-seven patients with CD20(+) B-NHL in relapse or induction failure received Rituximab combined with DexaBEAM (R-DexaBEAM) for stem cell mobilization. Additional ex vivo selection of CD34-positive cells was performed using the CliniMacs device. Two doses of Rituximab were included in the high-dose therapy regimen (HDT). R-DexaBEAM was well tolerated and 26 of 27 patients mobilized sufficient numbers of CD34(+) blood stem cells. Application of R-DexaBEAM resulted in significant depletion of peripheral B cells. No t…

OncologyAdultMalemedicine.medical_specialtyLymphoma B-CellSalvage therapyAggressive lymphomaAntigens CD34Transplantation AutologousDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedAutologous stem-cell transplantationhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesCD20Salvage TherapyTransplantationPeripheral Blood Stem Cell Transplantationbiologybusiness.industryBone Marrow PurgingRemission InductionAntibodies MonoclonalHematologyMiddle AgedNeoplastic Cells CirculatingHematopoietic Stem Cell MobilizationSurgeryHematopoiesisTransplantationRegimenImmune Systembiology.proteinRituximabFemaleVirus ActivationStem cellbusinessRituximabmedicine.drugBone marrow transplantation
researchProduct

Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma

2022

Abstract Background: Information about the long-term tolerability of tafasitamab is still limited. Methods: 5 of 92 patients treated within a phase IIa study of single-agent tafasitamab in relapsed or refractory B NHL were followed for up to five years or longer for long-term tolerability. Results: Treatment was very well tolerated in an outpatient setting with no hospitalizations needed and mild and tolerable adverse events that occurred mostly within the first two years of treatment. Conclusions: Given the excellent tolerability and efficacy of tafasitamab this agent can be used to induce remission in relapsed or refractory lymphoma either alone or in combination with chemotherapy.

OncologyCancer Researchmedicine.medical_specialtyChemotherapybiologybusiness.industryAnti cd19medicine.medical_treatmentAntigens CD19CancerHematologyImmunotherapyAntibodies Monoclonal Humanizedmedicine.diseaseOncologyTolerabilityRefractoryInternal medicinebiology.proteinHumansMedicineLymphoma Large B-Cell DiffuseAntibodybusinessAdverse effectClinical Lymphoma Myeloma and Leukemia
researchProduct

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, m…

2016

BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to De…

OncologyMaleDenmarkProgrammed Cell Death 1 ReceptorCohort Studies0302 clinical medicineRecurrenceAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineTreatment FailureReed-Sternberg CellsHazard ratioHematologyHodgkin DiseaseVinblastineDacarbazineSTAT1 Transcription FactorItalylymphoma PET Hodgkin030220 oncology & carcinogenesisDisease ProgressionbiomarkerFemalemedicine.drugAdultmedicine.medical_specialtyDacarbazineAntigens Differentiation MyelomonocyticSettore MED/08 - Anatomia PatologicaVinblastineDisease-Free Survival03 medical and health sciencesBleomycinAntigens CDInternal medicineHumansRetrospective StudiesFluorodeoxyglucosebusiness.industryRetrospective cohort studyPET scanmedicine.diseaseLymphomaSurgeryABVDReed–Sternberg cellDoxorubicinPositron-Emission TomographyMultivariate Analysisclassical Hodgkin's lymphoma:PolandbusinessBiomarkers030215 immunology
researchProduct

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >5…

2018

Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34+ cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). To compare the efficacy of the RIC and TCD approaches, we evaluated the outcomes of patients age >50 years with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) who underwent allo-HCT from an HLA-matched donor with one of these strategies. Baseline characteristics were comparable in the patients receiving TCD (n = 204) and those receiving RIC (n = 151), except for a higher proportion o…

OncologyMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentCD34GVHDGraft vs Host DiseaseAntigens CD34Lymphocyte Depletion03 medical and health sciencesMyelogenous0302 clinical medicineRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansTransplantation HomologousIn patientAgedRetrospective StudiesTransplantationHematopoietic cellbusiness.industryRICHematopoietic Stem Cell TransplantationImmunosuppressionT-cell depletionHematologyAllogeneic hematopoietic cell transplantationMiddle AgedMyeloablative Agonistsmedicine.diseaseTransplantationLeukemiaLeukemia Myeloid Acute030220 oncology & carcinogenesisMyelodysplastic SyndromesFemalebusinessT cell depletion030215 immunology
researchProduct

CD1a: a novel biomarker for Barrett's metaplasia?

2003

educational book. Alexandria: American Society for Clinical Oncology, 2001: 226–44. 49 Hussain M, Smith DC, Al-Sukhun S, et al. Preliminary results of HER-2/neu screening and treatment with trastuzumab (Herceptin) (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in patients with advanced urothelial cancer. Proc Am Soc Clin Oncol 2002; 21: 800a. 50 Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 2003; 97 (8 suppl): 2064–75. 51 Hussain SA, Ganesan R, Hiller L, et al. Pro-apoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 2003; 88: 586–92. 52 Stein JP, Ginsberg DA, Grossfiel…

Oncologymedicine.medical_specialtyBladder cancerbusiness.industrymedicine.medical_treatmentCancermedicine.diseaseCarboplatinGemcitabineRadiation therapyAntigens CD1chemistry.chemical_compoundBarrett EsophagusTransitional cell carcinomaOncologychemistryPaclitaxelTrastuzumabInternal medicinemedicineHumansOncology CD1abusinessBiomarkersmedicine.drug
researchProduct

CD133 as a target for colon cancer.

2012

INTRODUCTION: Recent evidence based on cancer stem cell (CSC) models, is boosting the progress of translational research and providing relevant clinical implications in many tumour types, including colorectal cancer. The current failure of standard therapies is attributed to a small fraction of the primary cell population with stem-like characteristics, such as self-renewal and differentiation. Identification of CSCs is based on two different criteria of selection: stemness-selective conditions and direct isolation based on putative stem cell markers expression. CD133, a transmembrane glycoprotein, was associated with tumor-initiating cells derived from several histological variants of tumo…

Oncologymedicine.medical_specialtyColorectal cancerClinical BiochemistryCellPopulationTranslational researchBiologyStem cell markerAntigenCancer stem cellAntigens CDInternal medicineDrug DiscoverymedicineTransmembrane glycoproteinAnimalsHumansAC133 AntigeneducationGlycoproteinsPharmacologyeducation.field_of_studymedicine.diseasemedicine.anatomical_structureCD133 colon carcinogenesis colorectal CSCs stemness markers.Neoplastic Stem CellsMolecular MedicineColorectal NeoplasmsPeptides
researchProduct